Indications
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Composition
- Active substance
- amifampridine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Firdapse (previously Zenas)
- Active substance
- amifampridine
- ATC code
- N07XX05
- Group
- Nervous system
- Therapeutic area
- Lambert-Eaton Myasthenic Syndrome
- Marketing authorisation holder
- SERB SA
- Status
- Authorised
- EU authorisation
- 23 Dec 2009
- EMA product number
- EMEA/H/C/001032